世界*實驗材料供應商 Dianova 正式授權上海起發(fā)為其中國代理， Dianova 在一直是行業(yè)的*,一直為廣大科研客戶提供zui為的產品和服務,上海起發(fā)一直秉承為中國科研客戶帶來的產品，的服務，簽約 Dianova 就是為了給廣大科研客戶帶來更加完善的產品和服務,您的滿意將是我們zui大的收獲

 Dianova 中國代理, Dianova 上海代理， Dianova 北京代理，Dianova 廣東代理， Dianova 江蘇代理Dianova 湖北代理,Dianova 天津,Dianova 黑龍江代理,Dianova 內蒙古代理,Dianova 吉林代理,Dianova 福建代理, Dianova 江蘇代理, Dianova 浙江代理, Dianova 四川代理,

Dianova公司為德國的病理免疫組化產品供應商，具備的抗體制備工藝及嚴格的質控系統(tǒng)，產品在上享有良好的聲譽。

克隆號為H09的IDH1（isocitrate dehydrogenase 1, 異檸檬酸鹽脫氫酶1）鼠單克隆抗體為Dianova公司近期推出的產品之一，此抗體可特異性的檢測腦組織腫瘤中IDH1基因的R132H點突變。IDH1基因的第132密碼子的雜合突變是II 和III級神經膠質瘤（根據WHO的腫瘤學分類）的頻發(fā)事件。在大約70％的星形膠質細胞瘤和少突神經膠質細胞瘤可發(fā)現IDH1基因的R132H點突變。

IDH1基因R132H突變在部分腦腫瘤中的頻發(fā)現象使克隆號為H09的IDH1抗體可高靈敏性和高特異性的用于此類腫瘤的鑒別診斷中：如從原發(fā)性膠質母細胞瘤中區(qū)分出間變性星形細胞瘤、從毛細胞型星形細胞瘤或室管膜（細胞）瘤中區(qū)分出彌漫性星形細胞瘤（WHO分類II級），也可以用于具有IDH1突變的腫瘤細胞浸潤前沿的與反應性神經膠質增多癥的區(qū)分。因此，由于其高靈敏性和高特異性，此抗體在腦部腫瘤的分類分級中以及在檢測單一或少量浸潤腫瘤細胞時是非常有用的。

DIA-H09-L – Anti-IDH1 R132H (Hu) from Mouse (Clone: H09) – unconj. – 8 ml

Art.-Nr.                         DIA-H09-L

Specificity                      IDH1 R132H

Species Reactivity               Human

Host Species                     Mouse

Isotype                          IgG2a

Clone                             H09

Clonality (Mono-/Polyclonal)      monoclonal

Application                       Immunohistochemistry (IHC)

                                 Immunohistochemistry (Paraffin-embedded Sections)

Conjugation                       unconjugated

Dilution                          pre-diluted – ready-to-use

Format                             Ready-to-use

                                   prediluted antibody
                                   2% BSA
                                   0.05% NaN3

Product line / Topic                neurobiology

                                    tumor marker / biology
                                    immunohistochemistry

Intended Use                        for Research Use Only

Manufacturer / Brand                dianova

Reactivity

Antibody clone H09 reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sections from formalin-fixed brain tumor specimens. Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximay 70% of astrocytomas and oligodendroglial tumors. The high frequency and distribution of the IDH1 R132H mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma WHO grade II from pilocytic astrocytoma or ependymoma. Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis. This antibody is highly useful for tumor classification and in detecting single infiltrating tumor cells.

Immunohistochemistry of human IDH1 R132H in formalin-fixed paraffin-embedded brain tissue sections

A: Strong reaction of IDH1 mutation specific antibody clone H09 in tumor center of anaplastic oligoastrocytoma.
B: Infiltration zone of anaplastic astrocytoma with specific labelling of infiltrating glioma cells by antibody clone H09.
C: Identification of single tumor cells in white matter distant from tumor center with IDH1 mutation specific antibody clone H09.
D: Cortex infiltrated by oligodendroglioma with specific labelling of tumor cells by antibody clone H09.
E: Double staining of GFAP (glial fibrillary acidic protein, red) and clone H09 (brown) of oligodendroglioma infiltration zone demonstrating specific labelling of tumor cells but not of GFAP positive reactive astrocytes.
F: Strong reaction of IDH1 mutation specific antibody clone H09 with IDH1 R132H mutated diffuse astrocytoma (left) but not with wild type tumor (right).

A

B

C

D

E

F

(pictures courtesy of Prof. Dr. med. Andreas von Deimling, Department of Neuropathology, University Heidelberg / Clinical Co-operation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany)

References

1. Capper D et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118(5): 599-601, 2009
2. Capper D et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 20(1): 245-254, 2010
3. Preusser M et al. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clinical Neuropathology, 30(5):217-230, 2011
4. Van den Bent MJ et al. Interlaboratory comparison of IDH mutation detection. J Neurooncol 112:173–178, 2013
5. Schumacher T et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, DOI:10.1038/nature13387
6. David NL et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol., 131:803-820, 2016

部分產品信息如下：

我們公司zui大優(yōu)勢是強大的采購，

1：基本什么都能進口，血清，抗體，耗材，還有部分限制進口的，

2：貨品全，現經營過700多個品牌，基本所有生物試劑耗材都可以進口，特別是冷偏的產品那就更有優(yōu)勢，

3：提供加急服務，一般1-2周到貨，超過時限加急費全免

4：價格公道，絕大部分價格有優(yōu)勢，當然不能保證100%產品都是,因為意味著沒有服務.

5：良好的信譽，大部分客戶我們提供貨到付款服務，客戶包括清華，北大 交大 復旦，中山等100多所大學，ROCHE，阿斯利康，國藥 ，fisher等500多家公司

6：我們還是Santa,Advanced Biotechnologies Inc, Dianova,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. Dako,Inc, GePromegaridege,Dianova  Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,Dianova , Polysciences,prospecbi, QA-BIO,quickzyme,FULLERLABS,INC,sterlitech；sysy,TriLink BioTechnologies,Inc；worthington-biochem,zyagen等幾十家國外公司授權代理。
7：我們還是invitrogen,qiagen,Midland BioProducts Corporationam,sigma;neb,roche,merck, rnd,BD, GE,pierce,BioLegend等知名*批發(fā)，歡迎合作。